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Abstract— Objectives: In arterial hypertension, amino-
terminal propeptide of type III procollagen (PIIINP) is 
elevated in arterial aneurysm tissue and associated with a 
poor prognosis following acute myocardial infarction 
(MI). Recombinant human growth hormone (rhGH) 
administration attenuates endothelial dysfunction but 
increases PIIINP. This study was conducted to establish if 
short-term rhGH administration affects PIIINP, 
endothelial function and selected cardiovascular disease 
(CVD) risk factors, in healthy males.  
Design: Method: Male subjects (n=48) were randomly 
assigned into two groups:  
(1): control group (C) n=24, mean ± SD, age 32 ± 11 
years; height 1.8 ± 0.06 metres;  
(2): rhGH administration group (rhGH) n=24, mean ± SD, 
age 32 ± 9 years; height 1.8 ± 0.07 metres. 
Blood pressure (BP), heart rate (HR), arterial pulse wave 
velocity (APWV), and biochemical indices were 
investigated.  
Results: PIIINP (0.28±0.1 vs. 0.42±0.2, U/ml); Insulin like 
growth factor-I (159±54 vs. 323±93, ng.mL-1); resting HR 
(72±14 vs. 78±11, b.p.m.) and rate pressure product (RPP) 
(90±18 vs. 97±14, bpm x mm.Hg x 10-2) all significantly 
increased (P<0.05). Total cholesterol (4.7±0.9 vs. 4.4±0.7, 
mmol.L-1); high sensitivity C-reactive protein (1.77±2.1 vs. 
1.29±1.6, mg.L-1); serum homocysteine (13.2±4.0 vs. 
11.7±3.1, μmol.L-1) and APWV (9.97±1.38 vs. 9.18±1.6, 
m.s-1) all significantly decreased (P<0.05).  
Conclusion: Paradoxically, there was an improvement in 
CVD inflammatory markers and APWV; but PIIINP and 
resting RPP increased.  
Elevated PIIINP may have a confounding adverse effect on 
the endothelium, but may also provide clinical prognostic 
information in monitoring arterial hypertension, left 
ventricular function in the sub-acute phase following MI 
and endothelial function in aortic aneurysms. 
Keywords— APWV; BP; hsCRP; Homocysteine; 
PIIINP; RPP.  
I. INTRODUCTION 
Serum amino-terminal propeptide of type III procollagen 
(PIIINP) is an extension peptide of procollagen type III and 
reflect its synthesis. It is cleaved off procollagen type III 
during the biosynthesis of type III collagen, and is a 
circulating biochemical marker of collagen metabolism 
which characterizes the early stages of repair and 
inflammation [1]. PIIINP is associated with the repair 
process involving collagen deposition which influences 
endothelial remodeling after myocardial infarction (MI) 
and increasing levels from ~3 to ≥ 5 µg/L are believed to 
reflect enhanced collagen turnover, including synthesis and 
deposition as well as alteration in degradation and 
elimination [1]. Elevated levels appear to be associated 
with a poor prognosis of patients following acute non-
thrombolysed MI [2]. An elevation of PIIINP greater than 
5.0 µg/L has been identified as an independent predictor of 
cardiac death or complicating left ventricular heart failure 
by vascular remodeling [3]. In dilated cardiomyopathy, 
with restrictive mitral filling pattern and diastolic 
dysfunction patients with an elevated PIIINP had a worse 
prognosis [4]. Elevated circulating levels of PIIINP were 
also associated with a decreased six minute walk distance 
and an increased resting heart rate (HR) in pulmonary 
arterial hypertension (PAH) [5]. 
PIIINP appears to be an important biomarker which may 
evaluate left ventricular end-diastolic pressure (LVEDP) 
and may predict cardiac mortality in acute coronary 
syndrome (ACS) [6].  
Collagen is an important protein of the extracellular matrix 
(ECM) that determines the physiological properties of 
arteries, especially the aortic wall and the development of 
abdominal aortic aneurysms (AAA) [7]. PIIINP is 
increased in AAA tissue compared with normal aortic 
walls affected by occlusive atherosclerotic disease [7]. A 
significant difference between plasma PIIINP levels exists 
in patients with AAAs compared with controls and the 
turnover of type III collagen increases with the 
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enlargement of the aneurysm diameter [8]. Degradation of 
type III collagen in the aneurysmal wall may have an 
important impact on AAA rupture and the increased levels 
of PIIINP may also be able to predict AAA prognosis [9].  
Collagen production has been identified as being increased 
in excess growth hormone (GH) production (acromegaly) 
[10]. Serum PIIINP which is increased in this condition 
may be used as a marker for monitoring the extent of the 
disease process [10]. Untreated long standing acromegaly 
is characterised by a high HR and arterial hypertension (the 
hyperkinetic syndrome) and concentric biventricular 
hypertrophy, diastolic dysfunction, rhythm disturbances 
and valve dysfunction which can all exacerbate 
acromegalic cardiomyopathy [11]. 
Systolic function and cardiac performance is markedly 
decreased in growth hormone deficiency (GHD) but is 
improved following recombinant human growth hormone 
(rhGH) replacement [12]. Endothelial dysfunction (ED) 
determined by flow-mediated endothelium-dependent 
dilation (EDD) of the brachial artery and measured by B 
mode ultrasound is prevalent in GH-deficient adults, which 
is reversed by rhGH replacement for the period of 
treatment of 18 months [13]. RhGH decreases aortic 
systolic and diastolic pressure which may reduce 
cardiovascular disease (CVD) in GHD [14]. RhGH 
improves vascular ED in patients with chronic heart failure 
who are not deficient in endogenous growth hormone [15].  
Short-term rhGH, four weeks (0.1 and 0.2 IU.kg-1.day-1) 
and two weeks (0.1 IU.kg-1.day-1) respectively, has been 
shown to significantly elevate PIIINP in healthy 
individuals by almost three times baseline levels [16, 17]. 
The purpose of this original study was to examine the 
effects of one week’s supraphysiological rhGH 
administration on PIIINP and specific CVD parameters in 
an apparently healthy group of strength training males. The 
research team hypothesised that PIIINP would increase and 




Subjects. Approval for the study was obtained from the 
University of South Wales ethics committee, in accordance 
with the declaration of Helsinki. Ethical registration 
committee number: HRE916. Prior to data collection, 
subjects were informed of experimental protocol, signed 
informed consent, and were instructed that they could 
withdraw from the study at any time. In addition, a drug 
screen was performed on each subject to exclude the use of 
xenobiotic substances. Urinalysis was performed at a 
world anti-doping agency (WADA) accredited laboratory. 
All subjects were recreational strength trainers and 
recreationally active. Subjects in both groups were former 
testosterone users and followed synchronised training 
times and intensity, which did not differ. This was verified 
by detailed training diaries. In order to avoid confounding 
effects on biochemical indices, subjects abstained from 
physical activity for 24 hours before each testing day.  
Study design. Male subjects (n=48) were randomly 
assigned, using a single blind procedure, into two groups:  
(1): control group (C) n=24, mean ± SD, age 32 ± 11 years; 
height 1.8 ± 0.06 metres;  
2): rhGH administration group (rhGH) n=24, mean ± SD, 
age 32 ± 9 years; height 1.8 ± 0.07 metres. 
Physiological tests were performed in the same order for 
both the experimental group and the control group. 
Subjects were familiarised with testing procedures. 
Subjects were examined daily over a period of six weeks 
between the hours of 09:00 and 11:00, to avoid 
confounding diurnal effects and were anonymous to each 
other. A dosage of 0.019 mg.kg-1.day-1 rhGH was used and 
was considered an acceptable dosage that would provide a 
physiological effect, with minimal side effects, in 
apparently healthy subjects. An administration diary was 
recorded. Subjects were examined prior to the 
commencement of rhGH administration, day 1, day 7, and 
after cessation, day 14. Dietary intake was strictly 
monitored, using a fourteen day dietary recall (Nutri-
check, Heath Options Ltd, Eastbourne, UK). 
Blood sampling. Phlebotomy was conducted in the fasted 
state, following 30 minutes rest in the supine position [18] 
using the standard venepuncture method (Becton 
Dickinson, Rutherford, NJ, USA between the hours of 
09:00 and 09:30 accounting for diurnal biological variation 
of male sex hormones [19].  
Serum analytes were measured using standard methods and 
analysed in duplicate. Serum total cholesterol (TC) and 
triglycerides (TG) were measured by dry-slide technology 
on an Ortho Vitros 950 analyzer (Ortho Clinical 
Diagnostics, High Wycombe, Bucks UK). The inter-assay 
CVs were: Total cholesterol: 1.95%; Triglycerides: 3.6%. 
The intra-assay CVs were: Total cholesterol: 3.8%; 
Triglycerides: 0.9%.  
Serum high density lipoprotein cholesterol (HDL-C) was 
analysed on an ILab 600 using a homogeneous direct 
method in which reaction with non-HDL cholesterol is 
prevented by addition of anti-human lipoprotein antibody 
(Instrumentation Laboratory, Warrington, UK). The inter-
assay CV was: 2.8%. The intra-assay CV was: 1.2%. 
Serum low density lipoprotein cholesterol (LDL-C) was 
derived from the Friedewald equation.  
High sensitivity C-reactive protein (hsCRP) was analysed 
using a latex-enhanced immunoturbimetric assay (Randox 
Laboratories, Crumlin, Northern Ireland). The inter-assay 
was: 4.95%. The intra-assay CV was: 8%. 
HCY was measured from plasma blood by fluorescence 
polarization immunoassay (FPIA) using the IMX® system 
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analyser IMX® reagents (ABBOTT Laboratories, UK). The 
inter-assay was: 6.1%. The intra-assay CV was: 4.4%. 
Testosterone (T, nmol.L-1) was analysed with the 
chemiluminescent immunoassay on an Advia Centaur 
analyser (Bayer Diagnostics, Newbury, UK). The inter-
assay CV was: 12.0%. The intra-assay CV was: 7%. 
IGF-I was analysed using the standard Nichols Institute 
Diagnostics IGF-I immunoradiometric Assay (IRMA), 
which employs two region-restricted affinity purified 
polyclonal antibodies (Nichols Institute Diagnostics, San 
Ciemente, CA 92673 U.S.A.) calibrated against the world 
health authority 1st IRP IGF-I 87/518.  
The inter-assay CV was: 4.5%. The intra-assay CV was: 
10.0%, 6.3% and 5.7% at serum concentrations of 61.5, 
340.8 and 776.9 ng.ml-1 respectively. 
Recombinant and pituitary GH were analysed using 
two immunofluorometric assays, one measuring 22 
kiloDalton hGH and the other total hGH (22 and 20 
kiloDalton) [20]. The inter-assay CVs were: 10.0, 4.0, and 
5.4% at 1.7, 12.1 and 22.2 ng.ml-1, respectively. The intra-
assay CV was 5%. 
Serum amino-terminal propeptide of type III procollagen 
(PIIINP) was measured by a two-stage sandwich RIA (CIS 
Biointernational; Oris Industries, Gif-Sur-Yvette Cedex, 
France). The reported intra-assay variability at 0.8, 1.5 and 
4.0 U/ml is 2.9, 2.9 and 4.0% respectively. The inter-assay 
variability at 0.25, 1.5 and 5.6 U/ml is 11.3, 7.8 and 9.3% 
respectively. 
Body composition assessment. Body mass (BM, kg) was 
measured using a calibrated balanced weighing scales 
(Seca, Cranlea Ltd, UK) and stature was measured using a 
stadiometer (Seca, Cranlea Ltd, UK). All measurements 
were taken barefoot in briefs. Body Mass Index (BMI, 
kg.m-2) was calculated by dividing the subject’s weight in 
kilograms (kg) by the square of the subject’s stature in 
meters. Body density was determined using hydrostatic 
weighing procedures previously described by [21]. 
Following a familiarisation trial, underwater weight was 
determined five times. The mean of five trials was used as 
the criterion value. Gastrointestinal volume was assumed 
to be 0.1 litres (L) and residual lung volume (RLV) was 
estimated to be 24% of forced vital capacity and ranged 
from  0.9 L-1.4 L, which was within normal limits [22]. 
Body fat was estimated from body density, using the 
equation of Siri [23].   
Arterial Pulse Wave Velocity (APWV): was measured 
simultaneously and non-invasively in the supine subject’s 
arm and leg by oscillometry (time resolution ± 2 ms; QVL 
SciMed (Bristol, UK). The right arm and right leg were 
used for all the studies. PWV was derived as the distance 
between the proximal edges of each pair of cuffs divided 
by the transit time in m.s-1. Each recording of PWV took 
30 seconds. Throughout each study PWV was measured for 
the first 12 minutes (12 instructions). Each instruction 
consists of the artery being in a state of vascular occlusion, 
at a pressure of 65-70 mmHg, for 30 seconds. PWV was 
measured for the following 30 seconds, in a state of non-
occlusion. After 12 instructions, there was distal vascular 
occlusion for 5 minutes at a pressure of 65-70 mmHg 
(instruction 13). Following the five minute occlusion, 
PWV was repeatedly measured for a further 12 
instructions. Reproducibility of supine PWV was assessed 
by within-subject coefficients of variation over 30 min of 
consecutive measurements and of measurements repeated 
one month apart. All subjects attended in the fasted state 
and at the same time on the morning of each study, having 
avoided caffeine-containing beverages for 12 h. All 
interventions and measurements were preceded by a 
preliminary period of >20 minutes supine rest in a quiet, 
temperature-controlled room at 22°C [24].  
Electrocardiography: A resting 12 lead electrocardiogram 
(ECG) was performed on all subjects in accordance with 
the position statement outlined by the American Heart 
Association [25].  
Blood Pressure (BP) Measurement: Blood pressure (BP) 
was measured in accordance with the American Heart 
Association Council on High Blood Pressure Research 
(2005) [26]. BP measurements were obtained by a single 
physician at the beginning of the physical examination, 
using a calibrated mercury column sphygmomanometer 
(Yamasu, Kenzmedico Co., Ltd., Japan). BP was measured 
from the bared arm, with the subject seated on a chair, with 
a back support, for five minutes with both feet on the floor 
and legs uncrossed. The arm was supported at heart level 
and the appropriate sized cuff was used, ensuring 80% of 
the circumference of the subject’s arm was encircled. The 
Korotkoff sounds were measured from the brachial artery 
in the antecubital fossa, using the diaphragm of the 
stethoscope (Littmann, 3M, Loughborough, England, UK). 
BP was ascertained from both arms and if the difference 
was less than 10 mmHg the reading was taken from the 
right arm. All readings that were finally used were 
measured from the right arm, since there were no 
differences between the right and left arm. Two 
auscultatory measurements in each position were made at 
an interval of one minute and an average of those readings 
was used to represent the patient’s BP. If these readings did 
not agree to within 5 mm.Hg for SBP and DBP a further 
two readings were made and the average of those multiple 
readings was used. 
Calculations and Statistical analyses.  
From published research, the sample size of n=24, was 
estimated using the nomogram method described by 
Altman (1982) [27]. The proposed main variable for the 
effect of rhGH was considered to be IGF-I and the lowest 
dose of rhGH required to significantly increase IGF-I, in 
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healthy young men and women, has been estimated to be 
0.0025 mg.kg -1.day-1 [28]. From the critical difference 
equation, described by Fraser and Fogarty, (1989) [29], 
Healy et al., (2003) [30] estimated an increase in IGF-I of 
24% was required to demonstrate a physiological effect of 
IGF-I on metabolism, from rhGH administration. Velloso 
et al., (2013) [17] monitored a dosage of 0.033 mg.kg -
1.day-1/0.1 IU.kg -1.day-1, which significantly increased 
PIIINP (P<0.05).  A dosage of 0.019 mg.kg -1.day-1/0.058 
IU.kg -1.day-1 was assumed to be an acceptable dosage that 
would provide a physiological effect, with minimal side 
effects, in a cohort of apparently healthy subjects. 
Data were analysed using a computerised statistical 
package (PASW 22.0 for Windows, Surrey, England) 
using parametric statistics. Significance was set at the 
P<0.05 level. Data are presented as means ± standard 
deviation (SD). The power of the test was calculated at 
95%. Confirmation that all dependent variables were 
normally distributed was assessed via repeated 
Kolmogorov-Smirnov tests. Changes in selected 
dependent variables as a function of time and condition 
were assessed using a two way repeated measures analysis 
of variance (ANOVA). Following simple main and 
interaction effects, Bonferroni-corrected paired samples t-
tests were applied to make posteriori comparisons of the 
effect of time at each level of the condition factor. The rate 
pressure product (RPP) was calculated as heart rate 
multiplied by systolic SBP.  
 
III. RESULTS 
The urinary concentrations of testosterone were normal 
and the serum gonadotrophins and testosterone were within 
the reference range for eugonadal men (male serum 
testosterone: 10-35 nmol/L, table 4). Electrocardiography 
was unremarkable in all subjects, demonstrating no 
adverse effect of rhGH on cardiac electrical or rhythmical 
activity.  
There were no changes within the control group. 
Demographic characteristics of the subjects are presented 
in table 1. Body mass index (BMI, kg.m-2) significantly 
increased within the rhGH administration group 
(P<0.017). Body fat significantly decreased within the 
rhGH administration group (P<0.017).  
Values for APWV (m.s-1) are presented in table 2. The 
lower limb pre-occlusion velocity was significantly 
decreased within the rhGH administration group 
(P<0.017).  
Results of the effects of rhGH on the cardiovascular 
responses: heart rate (HR), systolic blood pressure (SBP), 
and rate pressure product (RPP) responses are shown in 
table 2. HR and RPP significantly increased on rhGH 
administration compared with the control group (P<0.05).  
Results of the effects of the drug on the serum analytes are 
shown in table 3. Serum Sodium, IGF-I and PIIINP 
significantly increased within the rhGH administration 
group (P<0.017) and IGF-I and PIIINP also significantly 
increased compared with controls (P<0.05). Serum hsCRP, 
HCY, and TC, all significantly decreased within the rhGH 
administration group (P<0.017). 
 
IV. DISCUSSION 
In this study the administration of rhGH at a dose of 0.019 
mg.kg-1.day-1 for six days, in apparently healthy individuals 
equated to a mean value of 1.6 mg per day, which was 
considered a supraphysiological dose. In healthy males and 
females, the GH level is normally undetectable (<0.2 μg.L-
1) throughout most of the day. There are approximately 10 
intermittent pulses of growth hormone per 24 hours, most 
often at night, when the level can be as high as 30 μg.L-1. 
This equates to an average GH secretion of circa 0.67 mg 
and 0.83 mg in males and females respectively, per 24 
hours [31]. 
The effect of rhGH in elevating PIIINP and IGF-I, 
corroborated similar research of short-term (four and two 
weeks) rhGH administration [16, 17]. PIIINP 
concentration is currently considered an independent 
predictor of left ventricular end-diastolic pressure 
(LVEDP) and correlates with cardiac mortality and 
revascularization, providing an additional means of 
evaluating and managing patients with acute coronary 
syndrome [6]. Arterial PWV is a valid and non-invasive 
measure of arterial stiffness that may be more directly 
related to damage of the target organs relative to brachial 
blood pressure as it is less altered by heart rate, wave 
reflection, and antihypertensive or lipid-lowering drugs 
[24]. It has only been suggested as a CVD correlational 
independent risk marker with PIIINP in recent years [5]. 
The mechanism by which rhGH exerts these effects is by 
the stimulation of collagen metabolism which is an 
important protein of the extracellular matrix (ECM) which 
determines the physiological properties and remodeling of 
the arterial endothelium in aortic aneurysms [7]. PIIINP 
also has an effect on myocardial fibroproliferation 
following myocardial infarction [3]. It is suggested that this 
increases arterial and myocardial stiffness, thereby causing 
systolic and diastolic blood pressure dysfunction resulting 
in BP elevation [4]. Cardiac echo-reflectivity, which is a 
reflection of heart collagen content, is increased in patients 
with active acromegaly and correlates with elevated 
PIIINP concentrations. After treatment of acromegaly, and 
reduction in GH production, both parameters revert to 
normal [32].  
Aortic APWV is also considered an important independent 
risk factor of CVD and an elevation can predict the 
International Journal of Advanced Engineering Research and Science (IJAERS)                      [Vol-4, Issue-7, July- 2017] 
https://dx.doi.org/10.22161/ijaers.4.7.26                                                                            ISSN: 2349-6495(P) | 2456-1908(O) 
www.ijaers.com                                                                                                                                                            Page | 168 
occurrence of cardiovascular events independently of 
classic risk factors, other than age and blood pressure [33]. 
The elasticity of the proximal large arteries is the result of 
the high elastin to collagen ratio in their walls, which 
progressively declines toward the periphery. Endothelium-
derived nitric oxide (NO) diffuses toward the underlying 
vascular smooth muscle, producing relaxation, modulating 
arterial smooth muscle tone and distensibility [34]. By 
improving arterial elasticity, endothelium-derived NO 
reduces the arterial wave reflection and reduces left 
ventricular work and the pulse pressure within the aorta 
[34].  
However, in acromegaly where GH and IGF-I levels are 
excessively elevated for prolonged periods of time there is 
increased oxidative stress coupled with diminished 
antioxidant capacity and the endothelial dysfunction 
occurs as a consequence of NO levels [35]. Both hydrogen 
sulfide (H2S) and nitric oxide (NO) are gaseous 
transmitters, which play a critical role in regulating 
vascular tone. An H2S and NO conjugated donor can time-
dependently and dose-dependently relax sustained 
contractions induced by phenylephrine in rat aortic rings, 
suggesting a possible interactive role between H2S and NO, 
in vasorelaxation, produced by fluctuating GH and IGF-I 
levels [36]. Also H2S induces relaxation of isolated rings 
of human mesenteric arteries, independently of NO. 
Endothelium-dependent related mechanisms with the 
stimulation of ATP-sensitive potassium channels 
represents important cellular mechanisms for H2S effect on 
human mesenteric arteries [37]. 
In this study, subjects were exposed to the shortest duration 
supraphysiological dosage of rhGH possible, which was 
considered to significantly increase PIIINP. This also 
caused a reduction in the lower limb pre-occlusion APWV. 
It is unknown whether the increase in PIIINP caused an 
increased turnover of the ECM in the arterial wall. The 
reasons for the decrease in APWV might be as a result of 
the increased IGF-I to a serum concentration where it 
increased NO [35]. IGF-I is believed to have a vascular 
protective role because it stimulates NO production from 
endothelial and vascular smooth muscle cells. The time 
frame and concentration levels of serum GH and IGF-I, 
from commencement of excess production, in acromegaly, 
to pathological symptomatology is still unknown. The 
research conducted by the GH-2000 and GH-2004 teams 
did not identify any serious adverse physiological effects 
despite the administration of double and quadruple the dose 
(0.033 and 0.067 mg.kg-1.day-1 [38, 16]) for four times 
longer (one month) than dosages used in the present study 
(0.019 mg.kg-1.day-1). However, the researchers were 
attempting to identify a test for doping rather than assess 
CVD risk factors. The significantly decreased lower limb 
pre-occlusion APW velocity in the rhGH group is 
comparable with the effects of rhGH on endothelial 
dysfunction (ED) in growth hormone deficiency (GHD) 
[14] and in heart failure [15]. 
The most common short term effects following rhGH 
administration are from sodium and water retention and 
weight gain, from dependent oedema, which can frequently 
occur within days [39]. It does this in GHD [39] and in 
healthy subjects by activation of the renin-angiotensin 
system, increasing aldosterone secretion, by inhibiting 
atrial natriuretic peptide secretion and by a direct action on 
renal tubules [40]. In the present study, the sodium level 
was significantly increased, but remained within the 
normal reference range, but this may have accounted for 
the elevation in resting HR and RPP, which occurs in 
acromegaly.  
Sustained increased plasma levels of IGF-I may predispose 
an individual to long term ED and may be accounted for by 
an inverse correlation of NO levels with GH and IGF-I 
excess [41]. In the present study the effect on HR and RPP 
which occurred, could be explained by the effects of IGF-I 
on NO production, impairing baroreceptor function, via 
activation of the NO-system, elevating HR without 
affecting BP [42], corroborating similar short-term rhGH 
administration [39]. 
The research group had previously identified a significant 
reduction of independent cardiovascular risk factors, 
following rhGH administration, without an identification 
of changes in PIIINP [43]. In coronary artery disease, 
hsCRP has an important function in initiation of 
inflammation. It is also a better predictor of mortality than 
fibrinogen and offers prognostic information beyond that 
provided by the conventional cardiovascular risk factors 
[44]. Also acute inflammation, determined by elevated 
hsCRP, significantly increases arterial stiffness (AS) in 
older adults [45]. These increases can be reduced in a high 
cardiorespiratory fitness group, compared with a low 
cardiorespiratory fitness group [45]. 
Raised levels of HCY and CRP, which are independent risk 
factors for atherosclerosis, are thought to elevate blood 
pressure and cause vascular endothelial dysfunction by 
reducing NO production in endothelial cells, potentiating 
oxidative stress, which may result in vasoconstriction and 
endothelin 1 increase [46]. 
This significant lowering of both HCY and hsCRP is a 
unique finding in an unusual cohort of former testosterone 
using individuals. It is believed that the use of 
supraphysiological dosages of testosterone sensitises these 
individuals to microvascular insult, which predisposes 
them to impaired vascular reactivity [47].  An elevation of 
HCY had previously been established by the authors’ 
research group in users of testosterone, which might 
account for the enhancement of oxidative stress and 
represent a mechanism leading to the destruction of 
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vascular cells [48]. In this study, the former users of 
testosterone had an elevation of homocysteine, which may 
have sensitised the arterial endothelium, initiated 
atherogenesis and increased AS by modification of DNA 
methylation [49]. The underlying epigenetic mechanism, 
which is an alteration of the phenotype without a change of 
DNA sequence, may have contributed to altered gene 
expression causing vascular damage [50]. However, 
following a twelve week washout the baseline values of 
HCY were within normal limits and the same as controls. 
By significantly lowering HCY, the administration of 
short-term rhGH would appear to have exerted a beneficial 
effect on any adverse effect that sustained elevated HCY 
might cause. 
The vascular protective role of IGF-I has been suggested 
because of its ability to stimulate NO production from 
endothelial and vascular smooth muscle cells [51]. IGF-I 
may also play a role in aging, atherosclerosis and 
cerebrovascular disease. Just as an excess of GH and IGF-
I can cause unfavourable cardiovascular effects [11, 32] so 
too in cross sectional studies, low GH and IGF-I levels 
have been associated with unfavourable CVD risk factors, 
such as abnormal lipoprotein levels and hypertension [51]. 
In prospective studies, lower IGF-I levels predict future 
development of ischaemic heart disease [51].  
Conclusion. The aim of the present study was to evaluate 
measurements of PIIINP, following short-term rhGH 
administration, as a diagnostic tool in relation to 
endothelial function. Despite the increase in PIIINP there 
was an improvement in APWV and CVD risk factors 
consistent with recent research [52]. We postulate that, 
over a longer period of time, an elevated PIIINP may 
ultimately have an adverse effect on endothelial structure 
and function and predict a future breakdown of the 
endothelium. We believe that such findings preclude the 
use of rhGH as either an adjunctive therapy in gender 
hormone replacement therapy (andropause and 
menopause) or as a solitary treatment of the somatopause. 
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Demographic characteristics of the subjects are presented in table 1. 
Table.1: Subject demographics. 















BM (kg) 89.8 ± 12.7 89.6 ± 12.6 89.5 ± 12.7 86.1 ± 12 86.7±12.1* 85.5±11.8** 
BMI (kg.m-2) 28 ± 3.1 27.9 ± 3.1 27.9 ± 3.1 27.5 ± 3.0 27.7 ± 3.1* 27.3 ± 3.0** 
Body Fat % 21.9 ± 3.8 21.7 ± 3.8 21.6 ± 4.0 20.0 ± 6.0 19.0 ± 6.0* 19.1 ± 5.8* 
RT (years.) 12.2 ± 3.6 12.2 ± 3.6 12.2 ± 3.6 12.2 ± 3.6 12.2 ± 3.6 12.2 ± 3.6 
   WT (no.week-1) 4.4 ± 1.1 4.4 ± 1.1 4.4 ± 1.1 4.4 ± 1.1 4.4 ± 1.1 4.4 ± 1.1 
TT (mins.) 47 ± 15 47 ± 15 47 ± 15 47 ±15 47 ± 15 47 ± 15 
Energy Intake 
(KJ.day-1) 
18050±4100 18100±2020 18175±3100 17900±3020 18450±3900 18100±2020 
Protein Intake  
(g.day-1) 
205 ± 60 195 ± 55 213 ± 45 207 ± 35 217 ± 65 210 ± 50 
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Training history for control (C) group v growth hormone (rhGH) group.   
Results are presented as means ± Standard Deviations (SD)  
BM = Body mass; BMI = Body mass index; FFMI = Fat free mass index; RT = Resistance training; WT = Weight training;  
TT = Training time. 
* = P<0.017 = significantly different to PRE- rhGH; ** = P<0.017 = significantly different to on-rhGH 
 
Values for Cardiovascular responses are presented in table 2.  
Table.2: Arterial Pulse Wave Velocity & Heart Rate and Blood Pressure Responses. 

















8.76  1.80 8.88  1.69 8.91  1.90 9.21  1.93 8.69  1.17 8.49  1.08 
UL-POST-OC-V 
(m.s-1) 
8.31  1.76 8.67  1.54 8.63  1.69 8.96  1.80 8.65  1.41 8.27  0.94 
LL-PRE-OCC-V 
(m.s-1) 
9.64  1.62 9.79  1.50 9.75  1.54 9.97  1.38 9.18  1.60* 9.26  1.52* 
LL- POST-OC-V 
(m.s-1) 





66 ± 16 
 
67 ± 16 
 
67 ± 14 
 
72 ± 14 
 
78 ± 11† 
 





125 ± 12 
 
124 ± 12 
 
125 ± 11 
 
126 ± 10 
 
125 ± 12 
 
122 ± 9 
       
 
APWV (m.s-1) responses for control (C) group v growth hormone (rhGH) group. 
Figures are presented as means ± Standard Deviations (SD).  
UL-PRE-OCC-V = Upper Limb Pre-occlusion Velocity;  
UL-POST-OC-V = Upper Limb Post-occlusion Velocity;  
LL-PRE-OCC-V = Lower Limb Pre-occlusion Velocity;  
LL-POST-OC-V = Lower Limb Post -occlusion Velocity. 
Heart rate (HR, bpm), Systolic Blood Pressure (SBP, mm.Hg),  
Rate Pressure Product (RPP, bpm. x mm.Hg x 10-2) responses, for control (C) group v growth hormone (rhGH) group.  
Figures are presented as means ± Standard Deviations (SD).  
–rest = Resting. 
† = P<0.05 = significantly different to C 
* = P<0.017 = significantly different to PRE-rhGH 
 
 
Serum analytes associated with cardiovascular disease (CVD) are presented in table 3. 
Table.3: Serum analytes associated with cardiovascular disease. 
Variables Control Group (C) Administration Group 




Day 1 7 14 1 7 14 
T (nmol.L-1) 17.5 ± 5.2 17.5 ± 5.6 17.4 ± 5.4 16.2 ± 6.0 15.3 ± 5.7 14.5 ± 5.0 
Na+ (mmol.L-1) 139.6 ± 8.4 141.5 ± 3.1 140.5 ± 5.8 140.6 ± 2.7 142 ± 2.4* 142 ± 2.4* 
hsCRP(mg.L-1) 1.35 ± 1.9 1.38 ± 2.1 1.44 ± 2.1 1.77 ± 2.1 1.29 ± 1.6* 1.7 ± 2.8 
HCY (μmol.L-1) 12.5 ± 4.2 13.3 ± 4.7 13.1 ± 4.1 13.2 ± 4.0 11.7 ± 3.1* 13.1 ± 4.3 
TG (mmol.L-1) 1.0 ± 0.4 1.1 ± 0.5 1.1 ± 0.4 1.2 ± 0.5 1.1 ± 0.6 1.4 ± 0.9 
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HDL (mmol.L-1) 1.2 ± 0.4 1.3 ± 0.3 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.2 1.2 ± 0.3 
LDL (mmol.L-1) 2.7 ± 0.8 2.8 ± 0.8 2.8 ± 1.0 2.9 ± 0.9 2.7 ± 0.7 2.9 ± 0.9 
TC (mmol.L-1) 4.4 ± 1.0 4.6 ± 0.9 4.5±1.1 4.7±0.9 4.4 ± 0.7* 4.7 ± 1.0 
IGF-I (ng.mL-1) 179 ± 47 169 ± 50 175 ± 53 159 ± 54 323±93*†¥ 175 ± 61 
PIIINP (U/ml) 0.32 ± 0.1 0.30 ± 0.1 0.32 ± 0.1 0.28 ± 0.1 0.42 ± 0.2*†¥ 0.35 ± 0.1* 
 
 
Serum analytes responses for control (C) group v growth hormone (GH) group.  
Figures are presented as means ± Standard Deviations (SD) 
T = Testosterone; hsCRP = high sensitivity C-reactive Protein; HCY = Homocysteine; TG = Triglycerides;  
HDL = High Density Lipoprotein; LDL = Low Density Lipoprotein; TC = Total Cholesterol;  
IGF-I = Insulin-like growth factor-I; PIIINP = Amino-terminal propeptide of type III procollagen.  
 
* = P<0.017 = significantly different to PRE-rhGH;  
† = P<0.017 = significantly different to POST-rhGH;  
¥ = P<0.05 = significantly different to C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
